



Robert has extensive experience in medical drug discovery and development

- Strong multidisciplinary research expertise in biochemistry and cell biology, within immunology/inflammation/oncology disease areas
- Development and adaptation of novel biochemical and cellular methodologies to achieve drug discovery goals
- Responsibility for discovery efforts that led to identification of potent and selective receptor agonists for relapsing multiple sclerosis, ulcerative colitis and Crohn's disease
- Member of a team that characterized in vitro and in vivo properties of an immunosuppressive biologic drug registered for treating rheumatoid arthritis
- Member and active participant of multidisciplinary teams (Project Working Group, Development Coordination Team, Target Product Profile Team), responsible for guiding clinical development and commercialization of several drugs
- Responsibility for preclinical development of a drug for the treatment of relapsing-remitting multiple sclerosis
- Member of joint steering committee for development of an in-licensed antibody for the treatment of eosinophilic esophagitis

Dr Robert Peach

1978 BSc in Zoology, UC

1988 MSc in Biochemistry, Lincoln University

1992 PhD in Biochemistry, University of Otago

Robert has over 25 years of drug discovery and development experience in the pharmaceutical and biotechnology industries.

On completing his PhD, he joined the Bristol-Myers Squibb Pharmaceutical Research Institute in Seattle, Washington, as a Postdoctoral Fellow. Robert progressed through to a senior research scientist, leading a research group in discovery and development of antibodies, receptors and inhibitors.

Robert then took up directorship roles at several pharmaceutical companies before co-founding Apoptos Inc. in 2007—a private biotechnology start-up focused on developing small molecule cancer drugs.

He then went on to co-found another biotechnology start-up, Receptos Inc. In 2013 Receptos became a public company

before being acquired by Celgene in 2015 for US\$7.8 billion. As Chief Scientific Officer at Receptos, Robert provided strategic leadership and direction of all aspects of research, preclinical and clinical development, licensing opportunities, and overall growth and direction of the company.

He is currently on the Board of Directors of Avalia Immunotherapies, Innate Immunotherapeutics, AdAlta and is a consultant for several other biotechnology companies.

Robert is the co-author of 75+ scientific publications and book chapters, and 20+ patents. His extensive drug discovery and development experience in autoimmune and inflammatory diseases, and cancer has resulted in multiple drugs entering clinical trials and 3 registered drugs so far.

